DelveInsight’s ‘Chronic Obstructive Pulmonary Disease (COPD)-Market Insights, Epidemiology, and Market Forecast–2032’ report delivers an in-depth understanding of the COPD, historical and forecasted epidemiology as well as the market trends in the United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan.
The COPD market report provides current treatment practices, emerging drugs, market share of the individual therapies, and the current and forecasted 7MM COPD market size from 2019 to 2032. The Report also covers current COPD treatment practice, market drivers, market barriers, SWOT analysis, reimbursement, market access, and unmet medical needs to curate the best of the opportunities and assesses the underlying potential of the market.
Some of the key facts of the Chronic Obstructive Pulmonary Disease Market Report:
Key Benefits of the Chronic Obstructive pulmonary disease Market report:
Got queries? Click here to know more about the Chronic Obstructive Pulmonary Disease Market Landscape
Chronic Obstructive Pulmonary Disease Overview
Chronic obstructive pulmonary disease (COPD) is a common, preventable, and treatable disease characterized by persistent respiratory symptoms and airflow limitation due to airway and/or alveolar abnormalities usually caused by significant exposure to noxious particles or gases.
The main risk factor for COPD is tobacco smoking, but other environmental exposures such as biomass fuel exposure and air pollution may contribute. Besides exposures, host factors predispose individuals to develop COPD. These include genetic abnormalities, abnormal lung development, and accelerated aging. Chronic and progressive dyspnea is the most characteristic symptom of COPD. Cough with sputum production is present in up to 30% of patients
Chronic Obstructive Pulmonary Disease Epidemiological Insight
Chronic Obstructive Pulmonary Disease Epidemiological Segmentation
Chronic Obstructive Pulmonary Disease Market Outlook
COPD prevalence is dramatically increasing worldwide; however, there are few effective therapies, and none of the treatments currently available prevent the progression of the disease or target all of the hallmark features. The development and progression of COPD are heterogeneous, which has hampered the development of new therapies.
Depending on the severity of the COPD, short-acting or long-acting bronchodilators were introduced. Short-acting bronchodilators last about 4–6 h and should be used when needed only. Long-acting bronchodilators last about 12 h or more and are used every day. Patients at risk of exacerbations began to use long-acting anticholinergics (LAMA) or combinations of inhaled long-acting β2-agonists (LABA) and corticosteroids (ICS). The LABA/LAMA combination was suggested for more symptomatic patients and those at greater exacerbation risk.
Roflumilast, a phosphodiesterase-4 inhibitor, is an alternative approach to prevent exacerbations in chronic bronchitis and a history of prior exacerbations. Although the overall approach was lauded for its personalized basis, many of the recommendations were not strictly evidence-based. A key limitation of these recommendations reflected the unclear role of ICS in COPD, with evidence suggesting that the widespread use of these agents persists.
COPD Market Drivers
COPD Market Barriers
Learn more by requesting for sample @chronic obstructive pulmonary disease Market Landscape
Chronic Obstructive Pulmonary Disease Key Companies
Chronic Obstructive Pulmonary Disease Therapies
Table of Contents
Click here to read more about chronic obstructive pulmonary disease Market
Media ContactCompany Name: DelveInsight Business Research LLPContact Person: Adya KaulEmail: Send EmailPhone: 9193216187Address:304 S. Jones Blvd #2432 City: Las VegasState: NevadaCountry: United StatesWebsite: https://www.delveinsight.com/